NDC 0310-1830

FASENRA

Benralizumab

FASENRA is a Subcutaneous Injection, Solution in the Human Prescription Drug category. It is labeled and distributed by Astrazeneca Pharmaceuticals Lp. The primary component is Benralizumab.

• Product ID: 0310-1830_3237584d-e4e2-49a4-b5a6-5c148cbdebf3
• NDC: 0310-1830
• Product Type: Human Prescription Drug
• Proprietary Name: FASENRA
• Generic Name: Benralizumab
• Dosage Form: Injection, Solution
• Route of Administration: SUBCUTANEOUS
• Marketing Start Date: 2019-10-04
• Marketing Category: BLA / BLA
• Application Number: BLA761070
• Labeler Name: AstraZeneca Pharmaceuticals LP
• Substance Name: BENRALIZUMAB
• Active Ingredient Strength: 30 mg/mL
• Pharm Classes: Interleukin-5 Receptor alpha-directed Cytolytic Antibody [EPC],Interleukin 5 Receptor alpha-directed Antibody Interactions [MoA]
• NDC Exclude Flag: N
• Listing Certified Through: 2021-12-31

Packaging

NDC 0310-1830-30

1 CARTRIDGE in 1 CARTON (0310-1830-30) > 1 mL in 1 CARTRIDGE

• Marketing Start Date: 2019-10-04
• NDC Exclude Flag: N
• Sample Package?: N

NDC SPL Data Element Entries

NDC 0310-1830-85 [00310183085]

FASENRA INJECTION, SOLUTION

• Marketing Category: BLA
• Application Number: BLA761070
• Product Type: HUMAN PRESCRIPTION DRUG
• Marketing Start Date: 2019-10-04

NDC 0310-1830-30 [00310183030]

FASENRA INJECTION, SOLUTION

• Marketing Category: BLA
• Application Number: BLA761070
• Product Type: HUMAN PRESCRIPTION DRUG
• Billing Unit: ML
• Marketing Start Date: 2019-10-04

Drug Details

Active Ingredients

Ingredient	Strength
BENRALIZUMAB	30 mg/mL

Pharmacological Class

• Interleukin-5 Receptor alpha-directed Cytolytic Antibody [EPC]
• Interleukin 5 Receptor alpha-directed Antibody Interactions [MoA]

NDC Crossover Matching brand name "FASENRA" or generic name "Benralizumab"

NDC	Brand Name	Generic Name
0310-1730	FASENRA	Benralizumab
0310-1830	FASENRA	Benralizumab